Viatris raises 2026 outlook as complex generics and patches drive growth

Transcript intelligence

What changed

Management raised the midpoint of its full-year 2026 revenue, EBITDA and EPS guidance. The call analysis points to strong North American complex-generic and transdermal demand and Greater China as growth drivers, while supply constraints in Europe and emerging markets remained a drag. Management also discussed a pending Pacira acquisition and expansion of manufacturing capacity.

Guidance delta

Raised full-year 2026 revenue, EBITDA and EPS guidance, with a 2% revenue growth outlook. The supplied call analysis does not provide the prior and revised guidance figures, so this summary does not quantify the change.

Key takeaways

• Management attributed growth to North American complex generics and transdermal products, alongside Greater China demand.
• The Pacira transaction is expected by management to be accretive and to add products and commercial capabilities; integration and the anticipated synergies remain execution items.
• Fast-acting meloxicam and Phase III readouts for selatogrel and cenerimod are important pipeline milestones; the analysis places the readouts in H1 2027.

Management priorities

• Expand manufacturing capacity and packaging for transdermal demand while addressing Nashik-related supply constraints.
• Advance commercialization plans for fast-acting meloxicam and women's health transdermal products.
• Integrate Pacira assets and pursue the stated pipeline and product milestones.